EuroIntervention 14 - May, 2008
Our latest edition includes what you've come to expect from our journal: Breaking First-in-Man (FIM) studies such as first reports concerning EXCELLA™; Two-year results from the PASSION and CUSTOM I trials and the three year follow-up of the D-DELFT study; Eight leading European experts giving us their opinions on the current DES vs BMS debate; Treating left main disease in diabetics with DES; And topping it all off, the EuroCTO club reporting on their experiences with the retrograde approach.
EIJ session @ PCR (Thursday 15 May - 12:00-13:30 - Room 122/123)
For the first time at EuroPCR, our own dedicated symposium chaired by our Editor-in-Chief Professor Patrick W. Serruys and Professor Carlo di Mario. The authors of the six best papers submitted to EuroIntervention – and published in the current edition if the journal– have been invited to present their work accompanied by expert commentary. Join us in this ground-breaking event!
The Third EuroIntervention Supplement
Our next supplement, scheduled for release in August to coincide with the ESC meeting in Munich, focuses on a burning issue in our field, the “Critical Appraisal of the Safety Concerns Tempering the Success of Drug-eluting stents”. Originally conceived during a recent ESC Taskforce on DES in Nice, our special supplement Guest Editors, Dr. Stephan Windecker, Dr. Joost Daemen and Dr. Donald Cutlip have sought to widen the scope both in content and design by inviting other international experts to provide an overview as well as critical analysis of current and future practice.